Aisyi Mururul, Andriastuti Murti, Kurniati Nia
Department of Pediatric Hematology Oncology, Indonesian National Cancer Center "Dharmais" Cancer Hospital, Jakarta, Indonesia. Email:
Department of Child Health, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2619-2624. doi: 10.31557/APJCP.2019.20.9.2619.
Background: Hyperglycaemia is a common side effect of steroid and L-asparaginase combinations, occurring most often during acute lymphoblastic leukemia (ALL) induction phase. To date in Indonesia, it has not been obtained data on the incidence of hyperglycemia in children with ALL in the induction phase and how the role of combinations of L-asparaginase and different type of steroid used. The purpose of this study is to determine the incidence of hyperglycemia in children ALL induction phase, knowing the difference between prednisone and dexamethasone (in combination with L-asparaginase) in causing hyperglycemia in children with ALL and determine the relationship of other factors related to hyperglycaemia. Methods: This was a prospective analytic study with a pre- and post-test design, conducted in three hospitals (Cipto Mangunkusumo Hospital, Dharmais Cancer Hospital, and Gatot Soebroto Hospital). Patient’s blood glucose levels (BGL) were checked at the 3rd (pretest), 4th, 5th and 6th week of protocol (post-test). Result: Of the 57 patients, 5.2% had hyperglycemia. The patients’ age ranged from 1.4 years old to 15.8 years old (6.7 years old). There was no relationship between age, central nervous system (CNS) infiltration, leukocytosis, Down syndrome, nutritional status, family history of diabetes, infections and ALL stratification with hyperglycemia (p>0.05). Dexamethasone has more chance of obtaining higher mean rate of change in BGL compared to prednisone. (p < 0.05; RR 10.68; CI 95% 1.52-74.73). Conclusion: The incidence of hyperglycemia in this study is 5.2%. Dexamethasone, in combination with L-asparaginase, despite having no difference in causing hyperglycemia, has an increased risk of changing BGL compared to prednisone.
高血糖是类固醇与L-天冬酰胺酶联合使用时常见的副作用,最常发生在急性淋巴细胞白血病(ALL)诱导期。在印度尼西亚,至今尚未获得关于ALL患儿诱导期高血糖发病率的数据,以及L-天冬酰胺酶与不同类型类固醇联合使用的作用情况。本研究的目的是确定ALL患儿诱导期高血糖的发病率,了解泼尼松和地塞米松(与L-天冬酰胺酶联合使用)在导致ALL患儿高血糖方面的差异,并确定与高血糖相关的其他因素之间的关系。方法:这是一项采用前后测试设计的前瞻性分析研究,在三家医院(西托·曼古库苏莫医院、达玛伊斯癌症医院和加托·苏布罗托医院)进行。在方案的第3周(预测试)、第4周、第5周和第6周(后测试)检查患者的血糖水平(BGL)。结果:57例患者中,5.2%发生高血糖。患者年龄在1.4岁至15.8岁之间(平均6.7岁)。年龄、中枢神经系统(CNS)浸润、白细胞增多、唐氏综合征、营养状况、糖尿病家族史、感染和ALL分层与高血糖之间均无关联(p>0.05)。与泼尼松相比,地塞米松导致BGL平均变化率更高的可能性更大(p<0.05;RR 10.68;95%CI 1.52 - 74.73)。结论:本研究中高血糖的发病率为5.2%。地塞米松与L-天冬酰胺酶联合使用,尽管在导致高血糖方面无差异,但与泼尼松相比,其导致BGL变化的风险增加。